Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 13/20 | 1.00 |
| ▸ | MAOB | P27338 | 13/20 | 1.00 |
| ▸ | CA12 | O43570 | 8/20 | 1.00 |
| ▸ | CA9 | Q16790 | 8/20 | 1.00 |
| ▸ | CA1 | P00915 | 6/20 | 0.72 |
| ▸ | CA4 | P22748 | 3/20 | 0.72 |
| ▸ | CA6 | P23280 | 3/20 | 0.69 |
| ▸ | CA7 | P43166 | 3/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.69 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 2/20 | 0.69 |
| ▸ | CA3 | P07451 | 1/20 | 0.69 |
| ▸ | CA5A | P35218 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23624807 | 0.86 | CA12 (0.75) | MAOAMAOBCA12CA9CA1 | |
| SCHEMBL24045405 | 0.85 | CA12 (0.82) | MAOAMAOBCA12CA9CA1 | |
| SCHEMBL12304245 | 0.85 | CA12 (0.81) | MAOAMAOBCA12CA9CA1 | |
| SCHEMBL8512573 | 0.84 | CA12 (1.00) | MAOAMAOBCA12CA9CA1 | |
| SCHEMBL30127638 | 0.84 | CA12 (1.00) | MAOAMAOBCA12CA9CA1 | |
| SCHEMBL15745920 | 0.83 | CA12 (1.00) | MAOAMAOBCA12CA9CA1 | |
| SCHEMBL31086804 | 0.82 | CA12 (0.77) | MAOAMAOBCA12CA9CA1 | |
| SCHEMBL9214643 | 0.82 | CA12 (0.77) | MAOAMAOBCA12CA9CA1 | |
| SCHEMBL31086623 | 0.82 | CA12 (0.77) | MAOAMAOBCA12CA9CA1 | |
| 7-Butoxycoumarin SCHEMBL6686295 | 0.82 | CA12 (1.00) | MAOAMAOBCA12CA9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148400-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | METASIGNAL THERAPEUTICS INC. (CA) | 2014-05-29 | — | — | US | disclosed |
| US-20140148400-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | METASIGNAL THERAPEUTICS INC. (CA) | 2014-05-29 | — | — | US | disclosed |
| US-20140148400-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | METASIGNAL THERAPEUTICS INC. (CA) | 2014-05-29 | — | — | US | disclosed |
| WO-2012070024-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | METASIGNAL THERAPEUTICS INC. (CA) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012070024-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | METASIGNAL THERAPEUTICS INC. (CA) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148400-A1 | CARBONIC ANHYDRASE INHIBITORS WITH ANTIMETASTATIC ACTIVITY | CA7, CA4, CA2 | MAOA 834/4885MAOB 1205/4885CA12 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.